Manchester is set to host groundbreaking clinical trials targeting glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, which has seen no significant therapeutic breakthroughs in 20 years. The trials, led by a consortium of local hospitals and research institutions, will test novel drug combinations and immunotherapy approaches.
Glioblastoma affects approximately 3,200 people annually in the UK, with a median survival rate of just 12-18 months post-diagnosis. Despite decades of research, standard treatments—surgery, radiation, and chemotherapy—have shown limited efficacy. “This initiative represents a critical step toward addressing an unmet medical need,” said a spokesperson for the Manchester Biomedical Research Centre.
Analysts note that the trials align with global efforts to explore immunotherapies for solid tumors, which have historically been less responsive than blood cancers. “If successful, this could pave the way for similar approaches elsewhere,” remarked an oncology researcher familiar with the project.
However, some experts caution that glioblastoma’s complexity makes rapid progress unlikely. “The blood-brain barrier and tumor heterogeneity remain formidable challenges,” a neuroscientist told Nature Reviews Clinical Oncology last month. Results from the first phase of trials are expected in 2025.